Bristol-based lawyers at international legal practice Osborne Clarke have advised Creo Medical Group plc – a medical device company based in Chepstow which is focused on the emerging field of surgical endoscopy – to raise up to £48.5 million through a share placing.
The proceeds will be used for extending the company’s clinical education programme, increasing the number of distribution agreements with third parties and partners worldwide, accelerating the roll-out of its products, growing its manufacturing capability and product range, looking to establish a presence in the United States, and exploring potential strategic mergers and acquisitions.
Creo Medical’s flagship product, called Speedboat, allows doctors to carry out surgical procedures without the need to puncture the skin.
The Osborne Clarke team that advised on the transaction was led by corporate partner Mark Wesker, assisted by associate Oliver Gingell.
Osborne Clarke has over 500 people at its offices in Bristol’s Temple Quay. Its corporate team is considered the go-to practice for many businesses in the life sciences and healthcare sector, working with leading global businesses, fast-growth start-ups and market challengers. The team advises at every stage of company development across all corporate areas, from equity and debt fundraising to M&A, IPOs and JVs.